Structure Therapeutics Inc (GPCR)

$28.68 +1.40 (5.13%)
Market Cap 1.57B
Revenue (ttm) 0.00
Net Income (ttm) -122.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,582,100
Avg Vol 1,070,038
Day's Range N/A - N/A
Shares Out 57.60M
Stochastic %K 81%
Beta -1.65
Analysts Strong Sell
Price Target $76.00

Company Profile

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in pre...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 457 1978
Address:
601 Gateway Boulevard, Suite 900, South San Francisco, United States
judgeyoung2
judgeyoung2 Oct. 7 at 4:04 AM
$GPCR $VKTX i think it’s safest to just own both. at the end of it all, both will probably be acquired lol.
1 · Reply
judgeyoung2
judgeyoung2 Oct. 7 at 4:03 AM
$GPCR starting a position
0 · Reply
brd03
brd03 Oct. 6 at 7:31 PM
$GPCR
0 · Reply
ParkerSpark
ParkerSpark Oct. 6 at 5:47 PM
$GPCR 💪
0 · Reply
Supplement
Supplement Oct. 6 at 2:15 PM
$GPCR
0 · Reply
BiotechAndAI94
BiotechAndAI94 Oct. 3 at 5:48 AM
$GPCR thinking of moving to $GLXY
1 · Reply
BioRich
BioRich Oct. 1 at 1:17 PM
$ALT @denzo2 Solid pick with $GPCR. $TERN has also shown consistent SP progress and $GUTS, the best of them all, has been on a heater too. Just think, for all of those $ALT'ers that are holding for the miracle...if they would have just sold for their inevitable tax benefit, they would have made their money back in any of these others. This is where emotional investing (hanging onto $ALT when it's pretty washed up) is keeping folks bag holders and stressed. Cheers!
0 · Reply
Gostrongx
Gostrongx Sep. 30 at 10:12 PM
$VKTX $GPCR gap up today. Will they be next and VKTX be left at the altar again.
1 · Reply
Meltingflame
Meltingflame Sep. 30 at 7:35 PM
$GPCR I don’t see any news. Perhaps, investors establishing positions ahead of the data to be released this Q4. Any indication when in Q4?
0 · Reply
Ticker_Licker
Ticker_Licker Sep. 30 at 7:31 PM
$GPCR always a pleasant sight when looking at a golden cross ⬆️
0 · Reply
Latest News on GPCR
Structure Therapeutics Inc. (GPCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 10, 2025, 1:54 PM EDT - 26 days ago

Structure Therapeutics Inc. (GPCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Aug 6, 2025, 4:01 PM EDT - 2 months ago

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

Jun 23, 2025, 6:10 PM EDT - 3 months ago

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

AMGN LLY NVO PFE REGN VKTX XBI

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

Jun 20, 2025, 7:30 PM EDT - 3 months ago

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?

Apr 14, 2025, 10:49 AM EDT - 6 months ago

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?

VKTX

Biotech stocks have been hit hard. Why they're a great value now.

Mar 27, 2025, 7:40 AM EDT - 6 months ago

Biotech stocks have been hit hard. Why they're a great value now.

PFE BHVN DNLI INSM MRK SWTX

Structure Therapeutics CEO on latest GLP-1 developments

Mar 24, 2025, 6:26 PM EDT - 7 months ago

Structure Therapeutics CEO on latest GLP-1 developments

Final Trade: PYPL, UBER, NKE, GPCR

Mar 24, 2025, 6:23 PM EDT - 7 months ago

Final Trade: PYPL, UBER, NKE, GPCR

NKE PYPL UBER

Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate

Mar 20, 2025, 9:28 AM EDT - 7 months ago

Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Jan 30, 2025, 8:30 AM EST - 8 months ago

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst

Jan 6, 2025, 2:53 PM EST - 9 months ago

Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst

VKTX

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Dec 17, 2024, 4:01 PM EST - 10 months ago

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Structure CEO on the competitive landscape for oral GLP-1 drugs

Dec 5, 2024, 6:17 PM EST - 10 months ago

Structure CEO on the competitive landscape for oral GLP-1 drugs

NVO

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

Nov 15, 2024, 8:30 AM EST - 11 months ago

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Nov 13, 2024, 4:01 PM EST - 11 months ago

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients

Oct 22, 2024, 2:07 PM EDT - 1 year ago

Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Aug 26, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

Aug 26, 2024, 12:00 PM EDT - 1 year ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

AMGN CRBP SRRK VKTX

Structure Therapeutics: Pay Attention To This Overlooked Player In GLP-1 Weight Loss Field

Aug 23, 2024, 3:17 PM EDT - 1 year ago

Structure Therapeutics: Pay Attention To This Overlooked Player In GLP-1 Weight Loss Field

Structure Therapeutics CEO on GLP drugs

Jun 11, 2024, 6:37 PM EDT - 1 year ago

Structure Therapeutics CEO on GLP drugs

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

Jun 7, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

Jun 5, 2024, 7:53 PM EDT - 1 year ago

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz

Jun 3, 2024, 6:27 PM EDT - 1 year ago

Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

Jun 3, 2024, 4:09 PM EDT - 1 year ago

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

Structure Therapeutics reports promising weight-loss drug data

Jun 3, 2024, 2:38 PM EDT - 1 year ago

Structure Therapeutics reports promising weight-loss drug data

Structure Therapeutics' stock jumps on weight-loss-pill trial results

Jun 3, 2024, 8:42 AM EDT - 1 year ago

Structure Therapeutics' stock jumps on weight-loss-pill trial results

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

Jun 3, 2024, 7:30 AM EDT - 1 year ago

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

May 7, 2024, 11:33 AM EDT - 1 year ago

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

AMGN LLY NVO ALT AZN VKTX

Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

Apr 16, 2024, 7:09 PM EDT - 1 year ago

Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

AMGN AZN LLY NVO PFE SNY VKTX

Wegovy and Zepbound Are King. Who's Coming for Their Crowns.

Mar 9, 2024, 2:30 AM EST - 1 year ago

Wegovy and Zepbound Are King. Who's Coming for Their Crowns.

NVO PFE VKTX

Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

Mar 8, 2024, 4:05 PM EST - 1 year ago

Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

Mar 8, 2024, 8:30 AM EST - 1 year ago

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

The weight loss drug market may soon get more crowded – here are the companies trying to enter the booming space

Jan 17, 2024, 3:40 PM EST - 1 year ago

The weight loss drug market may soon get more crowded – here are the companies trying to enter the booming space

VKTX TERN

Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?

Dec 20, 2023, 11:17 AM EST - 1 year ago

Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?

LLY NVO ALT AMGN VKTX

Structure Therapeutics reports promising results for weight-loss pill

Dec 18, 2023, 11:56 AM EST - 1 year ago

Structure Therapeutics reports promising results for weight-loss pill

New Shakeup Hits Obesity Pills. Structure Rolls Out Disappointing Data.

Dec 18, 2023, 11:29 AM EST - 1 year ago

New Shakeup Hits Obesity Pills. Structure Rolls Out Disappointing Data.

Structure's diabetes pill misses weight-loss expectations in mid-stage trial

Dec 18, 2023, 10:37 AM EST - 1 year ago

Structure's diabetes pill misses weight-loss expectations in mid-stage trial

Structure Therapeutics stock plunges on new GLP-1 drug data

Dec 18, 2023, 8:04 AM EST - 1 year ago

Structure Therapeutics stock plunges on new GLP-1 drug data

Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study

Dec 18, 2023, 7:30 AM EST - 1 year ago

Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study

Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

Nov 14, 2023, 4:10 PM EST - 2 years ago

Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

Structure Therapeutics: Tipping The Scales In Obesity Management

Oct 3, 2023, 11:28 PM EDT - 2 years ago

Structure Therapeutics: Tipping The Scales In Obesity Management

Final Trades: Rivian, Pfizer, Treasury Bonds and more

Sep 29, 2023, 6:26 PM EDT - 2 years ago

Final Trades: Rivian, Pfizer, Treasury Bonds and more

PFE RIVN TLT

Shares of biotech startup Structure Therapeutics surge more than 30% on promising obesity pill data

Sep 29, 2023, 12:02 PM EDT - 2 years ago

Shares of biotech startup Structure Therapeutics surge more than 30% on promising obesity pill data

Structure Therapeutics surges on promising early stage obesity drug data

Sep 29, 2023, 10:15 AM EDT - 2 years ago

Structure Therapeutics surges on promising early stage obesity drug data

Structure Therapeutics shares surge after positive results in weight-loss trial, $300 million private placement

Sep 29, 2023, 8:02 AM EDT - 2 years ago

Structure Therapeutics shares surge after positive results in weight-loss trial, $300 million private placement

Structure Therapeutics Announces $300 Million Private Placement Equity Financing

Sep 29, 2023, 7:32 AM EDT - 2 years ago

Structure Therapeutics Announces $300 Million Private Placement Equity Financing

Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update

Sep 29, 2023, 7:30 AM EDT - 2 years ago

Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update

Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

Aug 10, 2023, 4:05 PM EDT - 2 years ago

Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

judgeyoung2
judgeyoung2 Oct. 7 at 4:04 AM
$GPCR $VKTX i think it’s safest to just own both. at the end of it all, both will probably be acquired lol.
1 · Reply
judgeyoung2
judgeyoung2 Oct. 7 at 4:03 AM
$GPCR starting a position
0 · Reply
brd03
brd03 Oct. 6 at 7:31 PM
$GPCR
0 · Reply
ParkerSpark
ParkerSpark Oct. 6 at 5:47 PM
$GPCR 💪
0 · Reply
Supplement
Supplement Oct. 6 at 2:15 PM
$GPCR
0 · Reply
BiotechAndAI94
BiotechAndAI94 Oct. 3 at 5:48 AM
$GPCR thinking of moving to $GLXY
1 · Reply
BioRich
BioRich Oct. 1 at 1:17 PM
$ALT @denzo2 Solid pick with $GPCR. $TERN has also shown consistent SP progress and $GUTS, the best of them all, has been on a heater too. Just think, for all of those $ALT'ers that are holding for the miracle...if they would have just sold for their inevitable tax benefit, they would have made their money back in any of these others. This is where emotional investing (hanging onto $ALT when it's pretty washed up) is keeping folks bag holders and stressed. Cheers!
0 · Reply
Gostrongx
Gostrongx Sep. 30 at 10:12 PM
$VKTX $GPCR gap up today. Will they be next and VKTX be left at the altar again.
1 · Reply
Meltingflame
Meltingflame Sep. 30 at 7:35 PM
$GPCR I don’t see any news. Perhaps, investors establishing positions ahead of the data to be released this Q4. Any indication when in Q4?
0 · Reply
Ticker_Licker
Ticker_Licker Sep. 30 at 7:31 PM
$GPCR always a pleasant sight when looking at a golden cross ⬆️
0 · Reply
brd03
brd03 Sep. 30 at 7:22 PM
$GPCR Hope something’s up!!!
0 · Reply
BiotechAndAI94
BiotechAndAI94 Sep. 30 at 2:43 PM
$GPCR my investment here paying off nicely
0 · Reply
SweepCastApp
SweepCastApp Sep. 29 at 6:01 AM
$GPCR: Unusual Options Activity Alerted CALL flow observed 88x contracts at Strike price of $25 Exp on 12/19/2025 with Premium of $55K and showing NEUTRAL Sentiment
0 · Reply
twincam
twincam Sep. 29 at 4:10 AM
$GPCR feels like 💭💭💭 $GPCR 👀💊🎰🚀🔥💎
0 · Reply
twincam
twincam Sep. 27 at 1:33 PM
$GPCR $VKTX Why these two are hot targets • Viking ($VKTX): dual GLP-1/GIP agonist VK2735 now in a large Phase-3 obesity program (plus oral formulation with solid Phase-2 data). That’s late-stage, de-risking, and directly competitive with incumbents.  • Structure ($GPCR): lead asset GSBR-1290 is an oral small-molecule GLP-1R agonist in Phase-2, with a next-gen oral combo roadmap (GLP-1 + GIP/amylin/etc.). Oral GLP-1 is a strategic white-space. 
1 · Reply
twincam
twincam Sep. 27 at 6:18 AM
$VKTX $GPCR $NVO $MRK 💊 Big Pharma never likes going hungry at the patent cliff… that’s when they start shopping 🛒 for fresh pipelines. Untested or not, a new drug candidate is always cheaper than losing billions to generics.
0 · Reply
BiotechAndAI94
BiotechAndAI94 Sep. 26 at 6:09 PM
$GPCR Amylin (DACRA) asset for combinability. First in class small molecule for Amylin
0 · Reply
Creisi
Creisi Sep. 26 at 4:02 PM
$GPCR $MTSR $ALT $VKTX
0 · Reply
himsssss
himsssss Sep. 26 at 4:01 PM
GLP1 space is regaining momentum this month, except for one. $GPCR 1 month gain 40% $MTSR 1 month gain 60% $ALT 1 month gain 15% $VKTX 1 month loss 1%
1 · Reply
BiotechAndAI94
BiotechAndAI94 Sep. 25 at 3:50 PM
$GPCR has phase 2 ready muscle sparing small molecule pill
0 · Reply
JIMMYDAMA
JIMMYDAMA Sep. 24 at 7:58 PM
$GPCR $VKTX Noticed that as well any one have short interest numbers on GPCR?
1 · Reply
Bagholding_VKTX
Bagholding_VKTX Sep. 24 at 7:49 PM
$VKTX And $GPCR are going crazy. Something leaked. But nobody is sure who it's going to be between those two. Very interesting. Let's see tonight or tomorrow if there are some news..
3 · Reply